Etanercept and efalizumab treatment for high‐need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice

Abstract

Etanercept and efalizumab are effective and safe treatments of psoriasis, even in a high-need population. Etanercept was able to sustain the clinical improvement throughout 24 weeks, whereas efalizumab was not in 47% of subjects.